Antibody Protein ELISA Kit from MyBioSource header Telephone 1.858.633.0165          
1.855.MyBioSource
Fax 1.858.633.0166    Email sales@mybiosource.com 
tel/fax
menu1 Home Products Ordering Company Help menu7
bottom
   MyBioSource rightarrow Antibody rightarrow CDKN2A rightarrow Monoclonal CDKN2A  rightarrow LOG IN  rightarrow MY ACCOUNT  rightarrow CART CONTENTS  rightarrow CHECKOUT 
horiz bar
MyBioSource Menu separator
separator
ELISA Kit ELISA Kit
CLIA Kit CLIA Kit
PCR Kit PCR Kit
Monoclonal Antibody Monoclonal Antibody
Polyclonal Antibody Polyclonal Antibody
Secondary Antibody Secondary Antibody
Antigen Antigen
Biochemical Biochemical
cDNA Clone cDNA Clone
siRNA siRNA
Peptide Peptide
Recombinant/Purified Protein Rec./Purified Protein

Custom ELISA Kit Custom ELISA Kit
Custom Protein Custom Protein
Custom Antibody Custom Antibody
Antibody Matched Pairs Antibody Matched Pairs
Antibody & Corresponding Blocking Peptide Pairs Antibody Peptide Pairs
Phospho-Specific Antibodies Phospho Antibodies
Products by Disease Products by Disease
Products by Pathway Products by Pathway
Products by Tissue Products by Tissue

arrow Advanced Search
arrow Submit Technical Q&A
arrow International Distributors
arrow Contact Us
separator
Our Best Sellers moreseparator
separator
 • E. coli heat-labile Enterotoxin B-chain Antibody
 • Lactoferrin (LF) ELISA Kit
 • KBP-Type Peptidyl-Prolyl Cis-Trans Isomerase (slyD) Recombinant Protein
 • chromosome 15 open reading frame 48 (C15orf48) ELISA Kit
 • NOS - Nitric Oxide Synthase Antibody
 • UL123 Recombinant Protein
 • Uncharacterized metalloprotease yggG (yggG) Recombinant Protein
 • 25-hydroxy vitamin D (25 OH D) ELISA Kit
 • Neuregulin 1 (NRG-1) ELISA Kit
 • CDC-like kinase 2 (CLK2) Antibody
 • SMURF1 Antibody
 • Auxin-responsive protein IAA17 (IAA17) Recombinant Protein
 • PALS2 - VAM1 - MPP6 Peptide
 • Brain Derived Neurotrophic Factor (BDNF) ELISA Kit
 downarrow more ...
separator
separator
DatasheetFull DatasheetPrinter Friendly DatasheetPrint This DatasheetAdd to Compare ListHave Questions? Ask UsRequest for a Quotation today

anti-CDKN2A antibody :: Mouse p16INK4a/CDKN2 Monoclonal Antibody

Scan QR to view Datasheet Catalog #    MBS175053 anti-CDKN2A antibody
Unit / Price
0.1 mg  /  $245 +1 FREE 8GB USB
 
 Go to:   rightarrow  Product Names   rightarrow Product Info   rightarrow Accession #s   rightarrow Product Desc   rightarrow Diseases/Tissues/Pathways   rightarrow Applications   rightarrow References 
 Product Name   

p16INK4a/CDKN2 (CDKN2A), Monoclonal Antibody

★Popular Item★
 Also Known As   

Anti-p16INK4a/CDKN2 antibody (monoclonal)

 Product Synonym Names    Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3; cyclin-dependent kinase inhibitor 2A; ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A; CDK4 INHIBITOR; cyclin-dependent kinase inhibitor 2A(melanoma, p16, inhibits CDK4); Cyclin-dependent kinase 4 inhibitor A; Multiple tumor suppressor 1; Collaborator of ARF
 Product Gene Name   

anti-CDKN2A antibody

[Similar Products]
 Research Use Only    For Research Use Only. Not for use in diagnostic procedures.
Table BarTOPTable Bar
 OMIM    gene 606719
 3D Structure    ModBase 3D Structure for P42771
Section Bar
 Clonality    Monoclonal
 Isotype    IgG1
 Clone Number    IMD-16
 Host    Mouse
 Species Reactivity    No cross reactivity with other proteins.
Section Bar
 Form/Format    Lyophilized
Mouseascitesfluid,1.2%sodiumacetate,2mgBSA,with0.01mgNaN3aspreservative.
Section Bar
 Immunogen    Recombinant human p16 protein.
 Species    Human
 Reconstitution    1.2% sodium acetate or neutral PBS. If 1ml of PBS is used, the antibody concentration will be 100ug/ml.
Section Bar
 Preparation and Storage    At -20C for one year. After reconstitution, at 4C for one month. It can also be aliquotted and stored frozen at -20C for a longer time.

Avoid repeated freezing and thawing.
 ISO Certification    Manufactured in an ISO 9001:2008 Certified Laboratory.
 Other Notes    Small volumes of anti-CDKN2A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Table BarTOPTable Bar
 

Related Product Information for anti-CDKN2A antibody

   Description: Mouse IgG monoclonal antibody for p16INK4a/CDKN2, cyclin-dependent kinase inhibitor 2A (CDKN2A) detection. Tested with WB, IHC-F, ICC in Human. No cross reactivity with other proteins. Uniprot ID: P42771
Background: p16(INK4A), also known as cyclin-dependent kinase inhibitor 2A(CDKN2A), or multiple tumor suppressor 1(MTS1). The p16 gene(CDKN2A) was mapped to 9p21. The p16 gene encodes a negative regulator of the cell cycle. CDKN2 plays an important role during tumorigenesis or tumor progression in a significant proportion of pancreatic adenocarcinomas. Germ-line mutations in the CDKN2A tumor-suppressor gene have been linked to the development of melanoma in some families with inherited melanoma.
 Applications Tested/Suitable for anti-CDKN2A antibody   

Western Blot (WB), Immunohistochemistry (IHC) Formalin, Immunocytochemistry (ICC)

 Application Notes for anti-CDKN2A antibody    Western Blot

Concentration: 0.5-1 ug/mL
Tested Species: Human


Imunohistochemistry (Frozen Section)

Concentration: 1-2 ug/mL
Tested Species: Human



Immunocytochemistry

Concentration: 1 ug/mL
Tested Species: Human


Other applications have not been tested.
.
Optimal dilutions should be determined by end
Table BarTOPTable Bar
NCBI/Uniprot data below describe general gene information for CDKN2A. It may not necessarily be applicable to this product.
 NCBI GI #    3041660
 NCBI GeneID    1029
 NCBI Accession #    P42771.2 [Other Products]
Section Bar
 UniProt Primary Accession #    P42771 [Other Products]
 UniProt Secondary Accession #    O95440; Q15191; Q5VVJ5; Q96B52; Q9NP05; A5X2G7; D3DRK1 [Other Products]
 UniProt Related Accession #    P42771; Q8N726 [Other Products]
Table BarTOPTable Bar
 NCBI Official Full Name    Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3
 NCBI Official Synonym Full Names    cyclin-dependent kinase inhibitor 2A
 NCBI Official Symbol    CDKN2A [Similar Products]
 NCBI Official Synonym Symbols   
ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A
[Similar Products]
 NCBI Protein Information    cyclin-dependent kinase inhibitor 2A; CDK4 inhibitor p16-INK4; multiple tumor suppressor 1; cell cycle negative regulator beta; CDKN2A {ECO:0000312|EMBL:AAM77919.1}; cyclin-dependent kinase 4 inhibitor A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
 UniProt Protein Name    Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3
 UniProt Synonym Protein Names   
Cyclin-dependent kinase 4 inhibitor A; CDK4I; Multiple tumor suppressor 1; MTS-1; p16-INK4a; p16-INK4; p16INK4A
 Protein Family    Tumor suppressor
 UniProt Gene Name    CDKN2A [Similar Products]
 UniProt Synonym Gene Names    CDKN2; MTS1; CDK4I; MTS-1; p16-INK4; p16INK4A [Similar Products]
 UniProt Entry Name    CD2A1_HUMAN
Section Bar
 NCBI Summary for CDKN2A    This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012]
Section Bar
 UniProt Comments for CDKN2A    p16-INK4A: a cell-cycle regulatory protein that interacts with CDK4 and CDK6, inhibiting their ability to interact with cyclins D. Inhibits the phosphorylation of the retinoblastoma protein by CDK4 or CDK6, and entry into the S phase of the cell cycle. The p16INK4A and p14ARF proteins are encoded by CDKN2A, a known tumour suppressor gene in multiple cancers. CDKN2A is inactivated in 72% of cases of lung squamous cell carcinoma: 21% by epigenetic silencing by methylation, 18% inactivating mutation, 4% by exon 1b skipping, and 29% by homozygous deletion. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome, Li-Fraumeni syndrome, and the melanoma-astrocytoma syndrome. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Four alternatively spliced p16 isoforms have been reported. Two alternatively spliced isoforms of ARF have been reported.

Protein type: Nucleolus; Tumor suppressor; Cell cycle regulation

Chromosomal Location of Human Ortholog: 9p21

Cellular Component: nucleoplasm; nuclear body; protein complex; mitochondrion; cytoplasm; nucleolus; cytosol; nucleus

Molecular Function: cyclin-dependent protein kinase inhibitor activity; NF-kappaB binding; protein binding; DNA binding; p53 binding; ubiquitin-protein ligase inhibitor activity; protein kinase binding; transcription factor binding

Biological Process: protein polyubiquitination; positive regulation of apoptosis; positive regulation of transcription, DNA-dependent; regulation of protein stability; negative regulation of B cell proliferation; regulation of protein export from nucleus; negative regulation of cell proliferation; apoptotic mitochondrial changes; regulation of G2/M transition of mitotic cell cycle; somatic stem cell division; cell cycle arrest; negative regulation of immature T cell proliferation in the thymus; caspase activation; protein destabilization; transcription, DNA-dependent; protein stabilization; negative regulation of cyclin-dependent protein kinase activity; negative regulation of cell-matrix adhesion; positive regulation of protein sumoylation; inhibition of NF-kappaB transcription factor; Ras protein signal transduction; negative regulation of ubiquitin-protein ligase activity; negative regulation of phosphorylation; negative regulation of protein kinase activity; positive regulation of transcription from RNA polymerase II promoter; negative regulation of cell growth; positive regulation of DNA damage response, signal transduction by p53 class mediator; mitotic cell cycle; negative regulation of transcription, DNA-dependent; rRNA processing; G1/S transition of mitotic cell cycle

Disease: Melanoma-astrocytoma Syndrome; Melanoma, Cutaneous Malignant, Susceptibility To, 2; Melanoma-pancreatic Cancer Syndrome
Table BarTOPTable Bar
 Research Articles on CDKN2A    1. Association of two CDKN2A polymorphisms, rs11515 and rs3088440, with the severity of cervical neoplasia.
Table BarTOPTable Bar
 Precautions    All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
 Disclaimer    While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Table BarTOPTable Bar
Products associated with anti-CDKN2A antibodyPathways associated with anti-CDKN2A antibody
 Reference Product  PubMed Publications
 CDK4 antibody  >1000 publications with CDKN2A and CDK4
 CCND1 antibody  >874 publications with CDKN2A and CCND1
 TP53 antibody  >646 publications with CDKN2A and TP53
 MYC antibody  >445 publications with CDKN2A and MYC
 MDM2 antibody  >368 publications with CDKN2A and MDM2
 CDK6 antibody  >306 publications with CDKN2A and CDK6
 CDK2 antibody  >271 publications with CDKN2A and CDK2
 NPM1 antibody  >4 publications with CDKN2A and NPM1
 UBC antibody  >1 publications with CDKN2A and UBC
 Products by Pathway  Pathway Diagram
 Apoptosis Pathway antibodies  Apoptosis Pathway Diagram
 Apoptosis Modulation And Signaling Pathway antibodies  Apoptosis Modulation And Signaling Pathway Diagram
 Bladder Cancer Pathway antibodies  Bladder Cancer Pathway Diagram
 Bladder Cancer Pathway antibodies  Bladder Cancer Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cell Cycle, Mitotic Pathway antibodies  Cell Cycle, Mitotic Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cell Cycle Pathway antibodies  Cell Cycle Pathway Diagram
 Cellular Senescence Pathway antibodies  Cellular Senescence Pathway Diagram
Diseases associated with anti-CDKN2A antibodyOrgans/Tissues associated with anti-CDKN2A antibody
 Disease Name  Pubmed Publications
 Adenocarcinoma Antibodies  >1261 publications with CDKN2A and Adenocarcinoma
 Urogenital Neoplasms Antibodies  >1186 publications with CDKN2A and Urogenital Neoplasms
 Cell Transformation, Neoplastic Antibodies  >734 publications with CDKN2A and Cell Transformation, Neoplastic
 Lymphoma Antibodies  >690 publications with CDKN2A and Lymphoma
 Lung Neoplasms Antibodies  >661 publications with CDKN2A and Lung Neoplasms
 Neoplasms, Experimental Antibodies  >621 publications with CDKN2A and Neoplasms, Experimental
 Glioma Antibodies  >487 publications with CDKN2A and Glioma
 Pancreatic Neoplasms Antibodies  >443 publications with CDKN2A and Pancreatic Neoplasms
 Breast Neoplasms Antibodies  >424 publications with CDKN2A and Breast Neoplasms
 Brain Neoplasms Antibodies  >421 publications with CDKN2A and Brain Neoplasms
 Organ/Tissue Name  Pubmed Publications
 Blood Antibodies  >909 publications with CDKN2A and Blood
 Skin Antibodies  >803 publications with CDKN2A and Skin
 Lung Antibodies  >799 publications with CDKN2A and Lung
 Brain Antibodies  >502 publications with CDKN2A and Brain
 Liver Antibodies  >471 publications with CDKN2A and Liver
 Bone Antibodies  >378 publications with CDKN2A and Bone
 Lymph Node Antibodies  >328 publications with CDKN2A and Lymph Node
 Lymph Antibodies  >326 publications with CDKN2A and Lymph
 Stomach Antibodies  >298 publications with CDKN2A and Stomach
 Cervix Antibodies  >242 publications with CDKN2A and Cervix
Table BarTOPTable Bar
horiz bar
 SSL   Follow us on Facebook Follow us onTwitter Follow us on Google Plus Connect us on LinkedIn Subscribe to our RSS Feed for latest products and special promotions